PIK3CA and cancer: Ultimately, the study aims to investigate the potential beneficial effects a KD with low-carbohydrate intake as well as the effects of canagliflozin in preventing glycemia and enhancing the effectiveness of cancer treatment in PIK3CA-mutant BC patients treated with targeted therapy (alpelisib) and endocrine therapy (fulvestrant).